Kalray Announces the Availability of Its TURBOCARD4 Card: a Paradigm Shift in Compute Acceleration for Smart Vision and Gen-AI Data-indexing Applications
2.4.2024 19:57:00 EEST | Business Wire | Press release
Kalray (Euronext Growth Paris: ALKAL), a leading provider of hardware and software solutions to accelerate data intensive workflows from Cloud to Edge announces the commercial availability of its latest product, the TURBOCARD4 (TC4) acceleration card. Powered by four of Kalray’s latest generation of DPU processors, the TC4 targets the fast growing markets of AI-powered smart vision and data-indexing applications. The TC4 is manufactured in France, in the French plant of Asteelflash, one of the leading global manufacturers worldwide. Kalray already received an initial order of more than $1 million (hundreds of cards) 1 to be recognized this year.
TC4 TARGETS THE FAST GROWING COMPUTE ACCELERATION CARD MARKET
Whereas enterprises and data centers have to process an ever-growing amount of data, compute acceleration cards are getting more and more traction to bring the best performance and best power efficiency in data processing.
“The availability of our new TC4 acceleration card is a major step for Kalray to set the stage for the widespread adoption of our latest acceleration technology. The TC4 has already been selected by one of our major customers and we envision a fast commercial take-off due to the ever-increasing demand in data processing acceleration solutions”, shares Eric Baissus, Kalray CEO.
“In addition, we are very proud to announce that the TC4 is our first “made in France” product. The production is ramping up rapidly in the plant of the leading global manufacturer AsteelFlash in Langon”.
BUILT TO COMBINE AI AND CLASSICAL COMPUTING
TC4 embodies Kalray's vision in addressing the intricate demands of modern computing workloads. Housing four of the latest generation of Kalray’s DPUs, Coolidge2TM, in a single PCIe card, Kalray’s TC4 is designed to ensure customers can merge classical and AI-based processing technologies and create superior, efficiency-driven systems for the most processing-intensive AI applications. DPUs offer a very complementary architecture to GPUs, allowing for the processing of a large number of different operations in parallel in an asynchronous way. DPUs are well-suited for pre-processing data that is later used by GPUs or in the context of complex intelligent systems running many different algorithms in parallel.
TWO FAST GROWING MARKETS TARGETTED: THE SMART VISION MARKET…
TC4 is strategically targeted at two rapidly growing markets. The first one is the Smart Vision market. Smart vision applications play a pivotal role in transformative sectors such as Industrial, Health Science, or Smart City operations due to their ability to analyze visual data in real-time, make intelligent decisions, and automate complex processes. The smart vision market size was valued at USD 20.31 billion in 2023 which is forecasted to reach USD 175.72 billion by 2032, exhibiting a CAGR of 27.3% (Fortune Business Insights). These projections highlight the increasing demand of smart vision technologies across various industries, driven by advancements in AI and machine learning, and their application in automation, quality control, and enhanced operational efficiencies.
…AND THE DATA-INDEXING FOR GEN-AI MARKET
In the context of Generative AI, data indexing is crucial for several reasons. Generative AI models, such as those used in natural language processing or image generation, often need to access enormous datasets. Efficient indexing minimizes the time required to fetch the relevant data, making the training and inference processes faster.
In addition, as Generative AI models become more complex, the datasets they train on grow exponentially. Data indexing allows these models to scale more effectively by ensuring that the increase in data volume does not linearly increase access times.
Data-Indexing also improves models’ outputs accuracy as indexing helps quickly identify the most relevant data pieces to insert in model context and prompt. This ensures that the model's outputs are as accurate and contextually appropriate as possible.
TC4 PRODUCTION HAS BEEN RE-LOCATED TO ASTEELFLASH FRENCH PLANT
Kalray's commitment to quality and desire to re-locate its production to Europe led to the alliance with Asteelflash for TC4 production. Asteelflash is one of the leading global electronic manufacturing services (EMS) companies, specializing in complex and high-tech manufacturing solutions across various industries. Asteelflash has several plants in Europe, including Germany and France. The TC4 production is performed in the Langon, France plant. This partnership has been supported by the French government as part of the CARAIBE funded project. The production volume is expected to grow from a few hundred per month today to several thousands of units per month, starting in 2025.
ABOUT KALRAY
Kalray is a leading provider of hardware and software technologies and solutions for high-performance, data-centric computing markets, from cloud to edge.
Kalray provides a full range of products to enable smarter, more efficient, and energy-wise data-intensive applications and infrastructures. Its offers include its unique patented DPU (Data Processing Unit) processors and acceleration cards as well as its leading-edge software-defined storage and data management offers. Separated or in combination, Kalray’s high-performance solutions allow its customers to improve the efficiency of data centers or design the best solutions in fast-growing sectors such as AI, Media & Entertainment, Life Sciences, Scientific Research, Edge Computing, Automotive and others.
Founded in 2008 as a spin-off of the well-known French CEA research lab, with corporate and financial investors such as Alliance Venture (Renault-Nissan-Mitsubishi), NXP Semiconductors or Bpifrance, Kalray is dedicated through technology, expertise, and passion to offer more: more for a smart world, more for the planet, more for customers and developers. www.kalrayinc.com
1 See press release as of 11th January, 2024
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240402257071/en/
Contact information
INVESTOR
E
ric BAISSUS
contactinvestisseurs@kalrayinc.com
Phone +33 4 76 18 90 71
ACTUS Finance & Communication
Anne-Pauline PETUREAUX
kalray@actus.fr
Phone + 33 1 53 67 36 72
PRESS
P
enta STANLEY
communication@kalrayinc.com
Phone +44 7939 877 880
ACTUS Finance & Communication
Serena BONI
sboni@actus.fr
Phone +33 4 72 18 04 92
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 10:00:00 EEST | Press release
SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter timeframes. The MoU underscores growing market adoption of SWISSto12’s HummingLink payload technology that leverages 3D-printing, with more than 2,000 pr
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 10:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly effective oral therapies that also address the diverse and often challenging manifestations of psoriasis, including involvement of high-impact sites like the scalp,” said Andy Plump, M.D., Ph.D., president of R&D at Takeda. “Our Phase 3 data demonstrated rapid and durable skin clearance across various patient types and in high-impact and hard-to-treat areas. Based on the results across nearly 3,000 patients, zaso
Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 10:00:00 EEST | Press release
According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, today announced the launch of Luna 8, its next-generation hardware security module. Designed for the transition to post-quantum cryptography, Luna 8 enables organizations to securely store, protect, and manage cryptographic keys with market-leading performance, scalability, and speed. As organizations face growing pressure from emerging quantum threats, expanding AI workloads and evolving stringent regulatory requirements, Luna 8 provides the performance, security and cryp
Focused Support Launches Cavok STRIKE to Expand Link-16 Participation Across the Joint Force14.9.2026 08:00:00 EEST | Press release
Focused Support LLC today announced the launch of Cavok STRIKE, an integrated software capability that expands the Link-16 tactical battlespace picture by enabling additional operational platforms to participate in the Link-16 network. Modern battlefields have increasing numbers of unmanned systems, sensors, and supporting platforms operating throughout the joint battlespace. The rapid proliferation of Group 1, 2, and 3 UAS, including both expendable and recoverable systems, has created a growing need to integrate these assets into the broader tactical network. Many of these platforms provide operationally relevant information but have historically remained outside the Link-16 network due to limitations in size, weight, power, platform integration complexity, or acquisition cost. Cavok STRIKE addresses this gap by enabling platforms to participate in the Link-16 network as non-command-and-control participants. This allows those platforms to interoperate with traditional Link-16 platfor
Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma14.9.2026 08:00:00 EEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE® G immunoassay platform in Brazil. “ANVISA authorization of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays marks another important step in our mission to expand access to reliable, clinically meaningful blood-based biomarkers for clinicians and patients worldwide,” said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “By making both neurological biomarker assays available to laboratories on a single, fully automated platform, we are helping support more informed clinical decision-making across a broad range of neurological conditions and throughout the diagnostic pathway.” The Brazilian ANVISA authorizations are based on the already CE marked in vitro diagnostics (IVD) approvals of these two
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom